HIKMA Pharmaceuticals PLC

AGM Information • Apr 25, 2022

National Storage Mechanism | Additional information

RNS Number : 2552J

Hikma Pharmaceuticals Plc

25 April 2022

Hikma Pharmaceuticals PLC

Results of 2022 Annual General Meeting

LONDON, 25 April 2022  Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at 1 New Burlington Place, W1S 2HR, London on 25 April 2022 commenced at 1:00 pm. Resolution 15 was withdrawn from the business of the meeting and all the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 14 were passed as ordinary resolutions and Resolutions and 16 to 20 were passed as special resolutions.

The shareholder support for the re-election of the Chair of the Nomination and Governance Committee (resolution 8) has reduced from circa 97% in 2021 to 69% today. Following feedback from shareholders prior to the meeting, the Board understands that this was due to the level of female representation on the board falling to 22% as at the end of the AGM following the retirement of Dr. Pamela Kirby.  The Board had envisaged that Dr. Kirby would step down in 2023 but understands that she wished to move on earlier than anticipated.  The Board is in the process of reviewing candidates to raise the level of female representation to meet or exceed its target of 33%.  The Board has noted the recent announcement from the FCA regarding gender diversity and is taking steps to ensure that these requirements are met within the established timeframe.  The Board will provide an update on progress within six months of the AGM and in the next annual report.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 23 February 2022) is set out below. The number of Ordinary Shares in issue on 25 April 2022 was 239,588,352.  There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 226,755,119.

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
1. To receive the 2021 report and accounts	171,860,023	100.00	2	0.00	171,860,025	1,357,656
2. To approve a final dividend of 36 cents per share	173,183,661	99.98	37,842	0.02	173,221,503	1,083
3. To re-appoint PricewaterhouseCoopers LLP as auditors	172,098,319	99.35	1,121,992	0.65	173,220,311	2,275
4.To authorise the Audit Committee to determine the auditors' remuneration	173,218,565	100.00	2,828	0.00	173,221,393	1,193
5. To re-elect Said Darwazah as a director	161,582,905	94.37	9,648,531	5.63	171,231,436	1,991,150
6. To re-elect Siggi Olafsson as a director	170,660,361	98.52	2,559,312	1.48	173,219,673	2,913
7. To re-elect Mazen Darwazah as a director	149,941,788	86.59	23,211,478	13.41	173,153,266	69,320
8. To re-elect Patrick Butler as a director	118,035,768	69.01	52,999,954	30.99	171,035,722	2,186,864
9.To re-elect Ali Al-Husry as a director	169,733,613	98.03	3,418,717	1.97	173,152,330	70,256
10. To re-elect John Castellani as a director	169,693,733	98.09	3,307,545	1.91	173,001,278	216,403
11. To re-elect Nina Henderson as a director	153,383,051	88.55	19,832,207	11.45	173,215,258	2,423
12. To re-elect Cynthia Flowers as a director	156,612,636	90.98	15,518,984	9.02	172,131,620	1,086,061
13. To re-elect Douglas Hurt as a director	153,843,021	88.82	19,370,952	11.18	173,213,973	3,708
14. To approve the remuneration report for the year ended 31 December 2021	157,785,532	91.09	15,426,369	8.91	173,211,901	5,780
15. Withdrawn	-	-	-	-	-	-
16. Authority to allot shares	164,319,344	95.46	7,812,300	4.54	172,131,644	1,086,037
17. To dis-apply pre-emption rights for general purposes	172,966,280	99.86	248,712	0.14	173,214,992	2,689
18. To dis-apply pre-emption rights for an acquisition or other capital investment	171,406,211	98.96	1,809,187	1.04	173,215,398	2,283
19. To authorise the Company to purchase its own shares	171,959,574	99.36	1,107,248	0.64	173,066,822	155,764
20. To authorise the Company to hold general meetings on no less than 14 clear days' notice	152,971,808	88.31	20,249,569	11.69	173,221,377	1,209

Declaration of final dividend

The dividend of 36 cents per share will be paid on 28 April 2022 to shareholders on the register on 18 March 2022.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.3021 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.709JD.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	+44 20 7399 2670
Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 20 7399 2670

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSEUFLIEESEDL